All articles by Vemula Pravalika
Vemula Pravalika
Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform
Novel Bosch BioMEMS technology helps save lives
QIAGEN launches new solution for screening of sexual assault forensic casework samples
QIAGEN today announced the launch of the Investigator Quantiplex Pro FLX Kit, which offers forensic laboratories highest sensitivity when processing casework samples. This enables researchers to reliably quantify DNA in the sample, allowing for informed downstream decisions in their workflow.
Scivita Medical Expands Collaboration with Boston Scientific
Recently, Scivita Medical Technology Co., Ltd. (“Scivita Medical”) and Boston Scientific Corporation (NYSE: BSX), a leading global medical technology company, joined hands again to sign an expanded strategic cooperation arrangement.
Seegene and Springer Nature Announce Awardees for the Open Innovation Program
Seegene Inc. (KQ096530), a leading South Korean company providing a total solution for PCR molecular diagnostics, and Springer Nature, a world-leading provider of services to the research community, unveiled the final list of participants for the diagnostic reagent development project on March 15, 2024(GMT), through the online platform of the Open Innovation Program (https://openinnovation.seegene.com/open-innovation/2023-2024-announcements/).
Chubb Launches HealthTech Industry Practice in UK
Chubb today announced the launch of a new HealthTech industry practice in the UK.
Abzena Announces Major Investment in Bioconjugation and ADC Capabilities in Response to Increasing Industry Demand
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site’s existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs.
QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of the QIAstat-Dx Analyzer 2.0, including the Software 1.6 upgrade, a significant enhancement to the widely-used QIAstat-Dx Analyzer 1.0 for reliable, fast and cost-effective diagnosis of complex syndromes.
eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient
eGenesis, a biotechnology company developing human-compatible engineered organs to address the global organ shortage, today announced the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.
Yes! We Can End TB & AIDS, Says AHF
AIDS Healthcare Foundation (AHF) country teams, which have prioritized screening for TB in clinics—along with preventing and treating HIV/TB co-infection—will hold World TB Day commemorations around the globe. (Graphic: Business Wire)
Microbix’s Clot-Buster Drug Project Advances
Sequel Pharma Executes Agreement with CDMO for Drug Substance Production